Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Kee Ming Chia"'
Autor:
Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon, Elgene Lim
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of
Externí odkaz:
https://doaj.org/article/b6f51a6926794f258d9ad544dc70f957
Autor:
Evangelia K. Papachristou, Kamal Kishore, Andrew N. Holding, Kate Harvey, Theodoros I. Roumeliotis, Chandra Sekhar Reddy Chilamakuri, Soleilmane Omarjee, Kee Ming Chia, Alex Swarbrick, Elgene Lim, Florian Markowetz, Matthew Eldridge, Rasmus Siersbaek, Clive S. D’Santos, Jason S. Carroll
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Chromatin-associated protein complexes play a critical role in the regulation of gene expression in health and disease. Here, the authors describe a sensitive mass spectrometry-based method to monitor the dynamic interactions of endogenous chromatin-
Externí odkaz:
https://doaj.org/article/6d77c38577f14fe9922378d351669816
Publikováno v:
Frontiers in Oncology, Vol 6 (2016)
MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions, maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation, and inhibiting its transcriptional activity. Both MDM2 and MDMX
Externí odkaz:
https://doaj.org/article/7d883c3ebed849e9ab6e8b8f8617179a
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 13, Iss 2, Pp 154-166 (2011)
Estrogen receptor (ER)-negative breast cancer is heterogeneous, and the biology of this disease has remained poorly understood. Molecular apocrine is a subtype of ER-negative breast cancer that is characterized by the overexpression of steroid-respon
Externí odkaz:
https://doaj.org/article/297d2fa5ca7949baad9266d65250c827
Autor:
Geraldine Laven-Law, Wilbert Zwart, Tarek M. A. Abdel-Fatah, Theresa E. Hickey, Mun N. Hui, Sarah Alexandrou, Luke A. Selth, Kee Ming Chia, Ian O. Ellis, C. Elizabeth Caldon, Daniel L. Roden, Jessica Finlay-Schultz, Suzan Stelloo, Shalini Jindal, Alexander Swarbrick, Wayne D. Tilley, Stephen N. Birrell, Carol A. Sartorius, Heloisa Helena Milioli, Richard Iggo, Carlo Palmieri, Esmaeil Ebrahimie, Jason S. Carroll, Elgene Lim
Publikováno v:
Nature Medicine, 27, pp. 310-320
Nature Medicine, 27, 310-320
NATURE MEDICINE
Nature Medicine, 27, 310-320
NATURE MEDICINE
The role of the androgen receptor (AR) in estrogen receptor (ER)-α-positive breast cancer is controversial, constraining implementation of AR-directed therapies. Using a diverse, clinically relevant panel of cell-line and patient-derived models, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fba0daa407197cbaf1a818ceffe24eb8
https://doi.org/10.1038/s41591-020-01168-7
https://doi.org/10.1038/s41591-020-01168-7
Autor:
Davendra Segara, Neil Portman, Kee Ming Chia, Allegra Freelander, Andrew Parker, Elgene Lim, Sanjeev Kumar
Publikováno v:
Current Opinion in Endocrine and Metabolic Research. 15:31-36
Estrogen receptor (ER) positive patient–derived xenograft (PDX) models of breast cancer are important translational tools in our pursuit for a better understanding of treatment resistance and for the preclinical evaluation of novel therapies. PDX m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96c18d7e7bb9852a6d8815b10528f682
https://doi.org/10.1016/j.coemr.2020.10.004
https://doi.org/10.1016/j.coemr.2020.10.004
Autor:
Joanna Achinger-Kawecka, Clare Stirzaker, Neil Portman, Elyssa Campbell, Kee-Ming Chia, Qian Du, Geraldine Laven-Law, Shalima S. Nair, Aliza Yong, Ashleigh Wilkinson, Samuel Clifton, Heloise H. Milioli, Sarah Alexandrou, C. Elizabeth Caldon, Jenny Song, Amanda Khoury, Braydon Meyer, Julia M.W. Gee, Anthony Schmitt, Emily S. Wong, Theresa E. Hickey, Elgene Lim, Susan J. Clark
Three-dimensional (3D) epigenome remodelling is emerging as an important mechanism of gene deregulation in cancer. However, its potential as a target to overcome cancer therapy resistance remains largely unaddressed. Here we show that treatment of en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f165cb5b806d5cd596741306b58a3a12
https://doi.org/10.1101/2021.06.21.449340
https://doi.org/10.1101/2021.06.21.449340
Autor:
Aliza Yong, Alexander Swarbrick, Liz Caldon, Kee Ming Chia, Wayne D. Tilley, Geraldine Laven-Law, Neil Portman, T Hickey, Elgene Lim, Heloisa Helena Milioli
Publikováno v:
Cancer Research. 79:P6-20
Introduction Resistance to endocrine therapy is a major clinical problem in estrogen receptor positive (ER+) breast cancer. The androgen receptor (AR) is expressed in ˜90% of all ER+ breast cancers and high expression of AR is associated with a bett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01bcaed6dd279b5b2465549888d1058b
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-04
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-04
Autor:
Wayne Tilley, Theresa Hickey, Luke Selth, Kee Ming Chia, Heloisa Milioli, Geraldine Laven-Law, Daniel Roden, Shalini Jindal, Mun Hui, Jessica Finlay-Schultz, Esmaeil Ebrahimie, Stephen Birrell, Suzan Stelloo, Richard Iggo, Sarah Alexandrou, C. Caldon, Tarek Abdel-Fatah, Ian Ellis, Wilbert Zwart, Carlo Palmieri, Carol Sartorius, Alexander Swarbrick, Elgene Lim, Jason Carroll
Antagonistic sex hormone activity occurs in mammary gland development, whereby estrogen stimulates and androgen inhibits post-pubertal growth, but the mechanistic basis of this is largely unknown. Whether sex hormone antagonism occurs in the context
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf2af7791ae2ff3c033218c98cee0f22
https://doi.org/10.21203/rs.3.rs-62718/v1
https://doi.org/10.21203/rs.3.rs-62718/v1
Autor:
Kee Ming Chia, Sarah Alexandrou, C. Elizabeth Caldon, Ensar Halilovic, Alexander Swarbrick, Rhiannon Coulson, Wayne D. Tilley, Heloisa Helena Milioli, Aliza Yong, Ygal Haupt, Neil Portman, Elgene Lim, Andrew Parker, Sue Haupt, Davendra Segara, Kristine J. Fernandez
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
Breast Cancer Research, Vol 22, Iss 1, Pp 1-17 (2020)
BackgroundResistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed via upregulation of its key re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::764a2796419a12da4e9278d3c7a6736a
http://europepmc.org/articles/PMC7425060
http://europepmc.org/articles/PMC7425060